Christopher I-Fu Li

Research Professor, Epidemiology



MD Medicine, University of California (San Francisco), 2000
PhD Epidemiology, University of Washington, 2003
MPH Epidemiology, University of Washington, 2000



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave N., M4-C308
P.O. 19024
Seattle, WA 98109
View Website »

Research Interests

Dr. Li is a cancer epidemiologist based at the Fred Hutchinson Cancer Research Center with research projects spanning cancer early detection/screening, etiology, and survivorship. He has significant expertise in cancer epidemiology and substantial experience in the design, leadership, and completion of multidisciplinary studies of cancer. Current research projects include: 1. A large population-based study of different molecular subtypes of breast cancer aimed at elucidating their risk factors and identifying novel subtype-specific tumor markers useful for predicting risk of disease recurrence (DOD Collaborative Innovator Award); 2. A nested case-control study of women with DCIS who did and did not go on to develop a second breast cancer aimed at developing novel epidemiologic, clinical, and molecular approaches for guiding clinical decision making for DCIS patients (R01); 3. Discovering and validating novel blood-based markers useful for the early detection of breast, colorectal, and ovarian cancers (U01); 4. Characterizing risk factors for second primary breast, lung, colorectal, and endometrial cancers among breast cancer survivors (R01); and 5. Discovering and validating novel biomarkers useful for assessing risk of recurrence among colorectal cancer survivors (R01 and U01). Selected leaderships activities include: 1. Serving as the co-PI of the Cancer Surveillance System (CSS), the Seattle-Puget Sound Surveillance, Epidemiology and End Results (SEER) cancer registry, 2. Chairing the DOD Breast Cancer Research Program’s Integration Panel (FY 2017), and 3. Co-chairing the 2017 AACR Conference on the Science of Cancer Health Disparities.

Recent Publications (PubMed)

Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic.
(2024 Feb 28)
J Behav Med
Aßmann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR

Allometric versus traditional body-shape indices and risk of colorectal cancer: a Mendelian randomization analysis.
(2024 Jan 31)
Int J Obes (Lond)
Rontogianni MO, Bouras E, Aglago EK, Freisling H, Murphy N, Cotterchio M, Hampe J, Lindblom A, Pai RK, Pharoah PDP, Phipps AI, van Duijnhoven FJB, Visvanathan K, van Guelpen B, Li CI, Brenner H, Pellatt AJ, Ogino S, Gunter MJ, Peters U, Christakoudi S, Tsilidis KK

Relationships Among Physical Activity, Sleep, and Cancer-related Fatigue: Results From the International ColoCare Study.
(2024 Feb 10)
Ann Behav Med 58(3): 156-166
Crowder SL, Li X, Himbert C, Viskochil R, Hoogland AI, Gudenkauf LM, Oswald LB, Gonzalez BD, Small BJ, Ulrich CM, Ose J, Peoples AR, Li CI, Shibata D, Toriola AT, Gigic B, Playdon MC, Hardikar S, Bower J, Siegel EM, Figueiredo JC, Jim HSL

Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.
(2024 Feb 6)
Cancer Epidemiol Biomarkers Prev 33(2): 288-297
Loroña NC, Othus M, Malone KE, Linden HM, Tang MC, Li CI

Data gaps and opportunities for modeling cancer health equity.
(2023 Nov 8)
J Natl Cancer Inst Monogr 2023(62): 246-254
Trentham-Dietz A, Corley DA, Del Vecchio NJ, Greenlee RT, Haas JS, Hubbard RA, Hughes AE, Kim JJ, Kobrin S, Li CI, Meza R, Neslund-Dudas CM, Tiro JA

Show complete publication list